Qlife Holding AB, Interim report Q2 2022
INCREASED FOCUS ON R&D ROADMAPFINANCIAL SUMMARY – SECOND QUARTER 2022 · Revenue in the period amounted to kSEK 4,025 (10.482). Revenue includes sales of Egoo.Health devices and capsules for the device. The decline in test activity following the end of European Covid restrictions has led to a decline in revenue in line with our expectations. · EBITDA for the period amounted to kSEK -20,623 (-8,024), and net loss kSEK -20,151 (-8,597). · The total cash flow in the second quarter amounted to kSEK -8,977 (98,938). · Earnings per share before/after dilution for the first